scholarly journals Features of the hemostasis system in patients with non-alcoholic fatty liver disease

2021 ◽  
Vol 55 (4) ◽  
pp. 235-238
Author(s):  
V.I. Didenko ◽  
S.L. Melanich ◽  
V.B. Yagmur ◽  
K.A. Ruban

Background. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. In recent years, disorders in the hemostasis system, their role in the progression of liver diseases and the development of cardiovascular complications in NAFLD have been actively studied. The purpose was to investigate the features of the hemostasis system in patients with non-alcoholic fatty liver disease. Materials and methods. We examined 36 individuals with NAFLD (20 women and 16 men) aged 29–73 years. All patients underwent an anthropometric, general clinical, biochemical study of blood serum with the determination of platelets, prothrombin time ratio, international normalized ratio, fibrinogen, ultrasound examination of the abdominal cavity organs with elastometry, followed by statistical data processing. Results. Among patients with NAFLD, class 2 obesity and overweight (30.6 % each), class 1 obesity (27.8 %) prevailed. At the same time, according to the controlled attenuation parameter, 38.9 % of people had a severe degree of steatosis, 33.3 % — moderate and 27.8 % — mild. Regarding the indicators of hemostasis, a significant increase in the level of fibrinogen up to (4.9 ± 0.5) g/l was detected in 44.4 % of patients, its severity tended to grow with an increase in the degree of hepatic steatosis. Conclusions. In 44.4 % of NAFLD patients, with an increase in the degree of hepatic steatosis, the tendency to hypercoagulability has grown with an increase in fibrinogen content by 1.6 times (p < 0.001). Changes in the international normalized ratio, prothrombin time ratio and platelets were determined in isolated cases: more than 83.3 % of patients with NAFLD didn’t have violations of these parameters.

2019 ◽  
Vol 20 (9) ◽  
pp. 2325 ◽  
Author(s):  
Hua Li ◽  
Wonbeak Yoo ◽  
Hye-Mi Park ◽  
Soo-Youn Lim ◽  
Dong-Ha Shin ◽  
...  

Arazyme, a metalloprotease from the spider Nephila clavata, exerts hepatoprotective activity in CCL4-induced acute hepatic injury. This study investigated the hepatoprotective effects in high-fat diet (HFD)-induced non-alcoholic fatty liver disease-like C57BL/6J mice. The mice were randomly divided into four groups (n = 10/group): the normal diet group, the HFD group, the arazyme group (HFD with 0.025% arazyme), and the milk thistle (MT) group (HFD with 0.1% MT). Dietary supplementation of arazyme for 13 weeks significantly lowered plasma triglyceride (TG) and non-esterified fatty acid levels. Suppression of HFD-induced hepatic steatosis in the arazyme group was caused by the reduced hepatic TG and total cholesterol (TC) contents. Arazyme supplementation decreased hepatic lipogenesis-related gene expression, sterol regulatory element-binding transcription protein 1 (Srebf1), fatty acid synthase (Fas), acetyl-CoA carboxylase 1 (Acc1), stearoyl-CoA desaturase-1 (Scd1), Scd2, glycerol-3-phosphate acyltransferase (Gpam), diacylglycerol O-acyltransferase 1 (Dgat1), and Dgat2. Arazyme directly reduced palmitic acid (PA)-induced TG accumulation in HepG2 cells. Arazyme suppressed macrophage infiltration and tumor necrosis factor α (Tnfa), interleukin-1β (Il1b), and chemokine-ligand-2 (Ccl2) expression in the liver, and inhibited secretion of TNFα and expression of inflammatory mediators, Tnfa, Il1b, Ccl2, Ccl3, Ccl4, and Ccl5, in PA-induced RAW264.7 cells. Arazyme effectively protected hepatic steatosis and steatohepatitis by inhibiting SREBP-1-mediated lipid accumulation and macrophage-mediated inflammation.


2019 ◽  
Vol 29 (7) ◽  
pp. 3564-3573 ◽  
Author(s):  
Jiulian Gu ◽  
Shousheng Liu ◽  
Shuixian Du ◽  
Qing Zhang ◽  
Jianhan Xiao ◽  
...  

2014 ◽  
Vol 31 (9) ◽  
pp. 1039-1046 ◽  
Author(s):  
S. J. Jenks ◽  
B. R. Conway ◽  
T. J. Hor ◽  
R. M. Williamson ◽  
S. McLachlan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document